Results published at the annual San Antonio Breast Cancer Symposium, said that Abraxane in combination with Xeloda may be an effective treatment option for patients with metastatic breast cancer.Abraxane is a newer form of Taxol that uses albumin, a natural protein found in the body, to deliver high concentrations of the active ingredient into the cancer cells and has fewer side effect than Taxol. Abraxane treatments last around 30 minutes compared with 3 hours for Taxol.

Researchers conducted a small clinical trial that included 38 patients with metastatic breast cancer. Complete disappearance of cancer was achieved in nearly 9 percent of patients. Partial responses were achieved in about 44 percent of patients. Disease stabilization was seen in almost 33 percent of study participants.

Even though the study was a small one, researchers conclude that it appears that treatment with Abraxane and Xeloda may be effective for patients with metastatic breast cancer.

In a clinical trial conducted at the University of Nottingham, scientists gave a vaccine to 67 colorectal cancer patients before and after surgery to remove the cancerous tumors. The British researchers say they have developed a vaccine that stimulates the immune system to fight colorectal cancer cells.Vaccine trials are not new in the search for effective cancer treatments but many times they are given as a last resort and are not effective. The vaccine is named 105AD7. The antibody in the vaccine was cloned from a patient who survived seven years despite liver metastasis from colorectal cancer. Lindy Durrant, study senior author and professor of cancer immunotherapy said “This is very unusual, as most patients die within a year of getting liver metastasis. I thought if this antibody had helped this patient, if we could clone it, it might help others”.

The researchers reported in the current issue of Clinical Cancer Research that the vaccine helped stimulate immune cell production in up to seventy percent of the patients studied.